Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Chini, Claudia C S; Guerrico, Anatilde M Gonzalez; Nin, Veronica; Camacho-Pereira, Juliana; Escande, Carlos; Barbosa, Maria Thereza; Chini, Eduardo N.
Clin Cancer Res
; 20(1): 120-30, 2014 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-24025713
Role of adipocytokines and its correlation with endocrine pancreatic function in patients with pancreatic cancer.
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.
Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
Identification of evolutionary and kinetic drivers of NAD-dependent signaling.
P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage.
Inflammatory macrophage dependence on NAD<sup>+</sup> salvage is a consequence of reactive oxygen species-mediated DNA damage.
METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis.
Recent advances in pancreatic cancer: biology, treatment, and prevention.
Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor ß signaling.
Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.